Clinical Nuclear Medicine · 2023 · 28 citations · 23 references
MedicineOncologyUrologyGenitourinary OncologyProstate DiseaseUrologic OncologyGenitourinary Cancer PharmacotherapyProstate CancerProstate Cancer ImagingProstate Cancer Radioligand TherapyProstate ImagingProstate-specific Antigen TestingClinical Evidence ReviewProstate Cancer DiagnosisProstate-specific Antigen - Targeted TherapyProstate-specific Membrane Antigen RadioligandsProstate-specific Membrane Antigen TargetingPsma-targeted TherapyRadioligand Therapy ImagingTargeted Radioligand Therapy
ABSTRACT: Diagnosis and treatment of prostate cancer are complex and very challenging, being a major health care burden. The efficacy of radioligand therapy with prostate-specific membrane antigen agents has been proven beneficial in certain clinical indications. In this review, we describe management of prostate cancer patients according to current guidelines, especially focusing on the available clinical evidence for prostate-specific membrane antigen radioligand therapy.
23
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Oliver Sartor, Johann S. de Bono, Kim N. et al. · New England Journal of Medicine · 2021 · 2.6K citations · Full text
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Karim Fizazi, NamPhuong Tran, Luis Fein et al. · New England Journal of Medicine · 2017 · 2.2K citations · Full text
Medicine, Oncology, Pharmacotherapy +15
Michael S. Hofman, John Violet, Rodney J. Hicks et al. · The Lancet Oncology · 2018 · 1.1K citations
Medicine, Nuclear Medicine, Oncology +14
Christos E. Kyriakopoulos, Yu‐Hui Chen, Michael A. Carducci et al. · Journal of Clinical Oncology · 2018 · 1.1K citations · Full text